Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
about
Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cellsROS and ROS-Mediated Cellular SignalingG-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer?Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.KRAS as a Therapeutic TargetActivation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer.Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumorsIn search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growthPhase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.Impaired coordination between signaling pathways is revealed in human colorectal cancer using single-cell mass cytometry of archival tissue blocksInhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinibRSK in tumorigenesis: connections to steroid signaling.Epidermal growth factor receptor-mediated regulation of urokinase plasminogen activator expression and glioblastoma invasion via C-SRC/MAPK/AP-1 signaling pathways.The critical role of ERK in death resistance and invasiveness of hypoxia-selected glioblastoma cells.Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.Mitogen-activated protein kinases in male reproductive functionEndothelial cell-derived interleukin-6 regulates tumor growth.Luteolin, a novel p90 ribosomal S6 kinase inhibitor, suppresses proliferation and migration in leukemia cellsHigh level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886)Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma.Bacillus Calmette Guerin induces fibroblast activation both directly and through macrophages in a mouse bladder cancer model.Characterization of ERK docking domain inhibitors that induce apoptosis by targeting Rsk-1 and caspase-9.Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.Melanoma: a model for testing new agents in combination therapies.Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinomaIdentification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma.Specific alterations of the microRNA transcriptome and global network structure in colorectal cancer after treatment with MAPK/ERK inhibitors.Intracellular electric field and pH optimize protein localization and movement.MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.LSF expression and its prognostic implication in colorectal cancerFunctional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition.Overexpression of eIF3e is correlated with colon tumor development and poor prognosis.Quantitative analysis of ERK2 interactions with substrate proteins: roles for kinase docking domains and activity in determining binding affinity.p53R2 inhibits the proliferation of human cancer cells in association with cell-cycle arrest.Extracellular regulated kinase 1/2 signaling is a critical regulator of interleukin-1β-mediated astrocyte tissue inhibitor of metalloproteinase-1 expression.MAPKs ERK and p38, but not JNK phosphorylation, modulate IL-6 and TNF-α secretion following OK-432 in vitro stimulation of purified human monocytes.Tumor hypoxia enhances Non-Small Cell Lung Cancer metastasis by selectively promoting macrophage M2 polarization through the activation of ERK signaling.
P2860
Q24300674-55328F7F-83CF-4D23-9F51-8C05EC5AC544Q26753142-B324E6BB-46EF-433F-B2AB-B8FFBDABC136Q26801162-B1E2DD14-76D5-405F-A8F5-49F81129F9CAQ26827810-732AC054-3BF7-42F5-BAE8-F5D8E19C49BCQ27007866-6D5D4496-32C2-4D54-BE8C-78C789D3C220Q27308683-54280BDD-861F-4930-943A-02AAACAAA146Q27349020-F669AC32-2EB7-47BC-8289-6761BA34F2FFQ28545022-E84DDD46-AC24-4469-B7EA-17FCA817F57EQ30313606-F2582704-2114-4C2B-966A-B02BC382EBF4Q30358990-75B9534A-D969-4E5C-B0F1-CB7B3BED3A96Q30422319-62CF6E79-936D-478D-8752-1B0CC929B32FQ30433106-F76D68E3-F54E-4FA7-8C8F-08A9EFABECFBQ30450853-C631ECAB-D508-4205-B169-7895983FFE8FQ33401981-4CC5DC87-183E-4F67-90D3-8930B6E15B1FQ33480990-DB9C7C20-87E3-427C-8DBD-44C10CA4363AQ33574315-C545DF9C-518A-408D-AF47-ECD1FECCFB34Q33584135-8270E2FC-B439-4BCC-AA1F-C8EDCF97C440Q33592677-6899B1BC-8F80-499B-B360-E22B6874D403Q33599474-BDCF0E36-AD55-40CA-9563-C6AB75AF0B03Q33717222-C699C6E1-C951-4FDA-9D47-9AE3160B9830Q33731418-7706B35F-57AF-4D47-853D-8A64DF565A91Q33735922-4C119374-6EC1-46B0-BD4E-6C754ADFE8A2Q33789572-D4A12268-897A-4B9E-BB6A-AA18F06FB8F1Q33820374-B6D6939B-479A-4D43-B90B-9A031BD70CCCQ33863916-8577DCBF-7E35-4B65-9872-14DC6B55B6DBQ33918198-608BF88E-3CBD-4237-A132-337AEFAB92CEQ33995206-28835D35-6086-4F00-95A4-B389EC0F2260Q34129528-F2669462-E087-44B8-9280-5C888BC6AD22Q34198061-FB2EE9EA-325C-402A-A400-B81C3961C13DQ34278697-84CEC6A4-EE20-4A14-B706-88D1B0D8AD39Q34279738-7615565B-D248-4F1B-9CCC-294D38E6ADB9Q34354215-0DFB32E3-276E-433C-8D5C-8A6DC961EC1FQ34371544-273FF861-92AD-4E0E-94BF-DE70518A598EQ34449946-51E3B87E-60DB-4C79-98A8-743FB6791FE5Q34502089-530B685A-E177-431A-B190-E0EBEB939AD7Q34509259-C2E30346-1EEE-49A6-A807-0A792CE34A41Q34592077-DE21A7A7-B352-4F7D-8028-7B09B1EC5CF0Q34607184-337B6405-F40B-4615-A4ED-41D90F79EE96Q34627443-7E7B06D7-C74E-4DB4-A249-EC2114BEA1F0Q34654565-CA7EF2F9-46C3-471D-A313-DCCB84423026
P2860
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Advances in targeting the Ras/ ...... inhibitors for cancer therapy.
@ast
Advances in targeting the Ras/ ...... inhibitors for cancer therapy.
@en
Advances in targeting the Ras/ ...... inhibitors for cancer therapy.
@nl
type
label
Advances in targeting the Ras/ ...... inhibitors for cancer therapy.
@ast
Advances in targeting the Ras/ ...... inhibitors for cancer therapy.
@en
Advances in targeting the Ras/ ...... inhibitors for cancer therapy.
@nl
prefLabel
Advances in targeting the Ras/ ...... inhibitors for cancer therapy.
@ast
Advances in targeting the Ras/ ...... inhibitors for cancer therapy.
@en
Advances in targeting the Ras/ ...... inhibitors for cancer therapy.
@nl
P1476
Advances in targeting the Ras/ ...... inhibitors for cancer therapy.
@en
P2093
Alex A Adjei
Bret B Friday
P304
P356
10.1158/1078-0432.CCR-07-4790
P407
P577
2008-01-01T00:00:00Z